{"status": "Ok", "redirect_url": "https://www.investor.jnj.com/investor-news/news-details/2026/RYBREVANT-FASPRO-amivantamab-and-hyaluronidase-lpuj-plus-LAZCLUZE-lazertinib-with-prophylactic-strategies-shows-low-rates-of-treatment-related-events-at-WCLC-2026/default.aspx", "message": "News view counter 933343 successfully enlarged"}